Tech Company Financing Transactions
Convergent Therapeutics Funding Round
Convergent Therapeutics secured a $90 million Series A funding round on 5/3/2023. Investors included OrbiMed, RA Capital Management and Invus.
Transaction Overview
Company Name
Announced On
5/3/2023
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Series A
Investors
Proceeds Purpose
he financing will support the development of a pipeline of novel radioantibodies, including its lead program with CONV01-a, for the treatment of advanced prostate cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Cambridge, MA Undisclosed
USA
Cambridge, MA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philip Kantoff
Chief Operating Officer
Alex Brown
Chief Scientific Officer
Neil Bander
Browse more venture capital transactions:
Prev: 5/3/2023: Origin by Ocean venture capital transaction
Next: 5/3/2023: CultureAI venture capital transaction
Share this article
Where The Data Comes From
We document funding rounds that are announced publicly. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs